Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling

László G. Puskás(University of Szeged), Michael A. James(Harvard University), Imola Mán(University of Szeged), Gábor J. Szebeni(University of Szeged), Susan Tsai(The Ohio State University Wexner Medical Center), László Tiszlavicz(University of Szeged)
Molecular Cancer Therapeutics
March 3, 2016
Cited by 21


Related Papers